Nuwellis Announces the Submission of the AVOID-HF Clinical Analysis as a Late Breaking Clinical Trial at HFSA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Stifel Reiterates Buy Rating on Baxter International (BAX)
July 28, 2022 9:57 AM EDTStifel analyst Rick Wise reiterated a Buy rating and $75.00 price target on Baxter International (NYSE: BAX)
The analyst comments "Macro challenges have been very much in evidence during initial 2Q22 MedTech reports. In Baxters 2Q, we are seeing the most significant negative... More
Evercore ISI on Baxter International (BAX) Guidance Update: 'we think the magnitude of the cut was a surprise'
July 28, 2022 9:55 AM EDTEvercore ISI analyst Vijay Kumar reiterated an Outperform rating and $80.00 price target on Baxter International (NYSE: BAX).
The analyst comments "BAX reported organic rev growth of ~3%, which came in ~1% below Guide expectations. Total revs of $3.74 Bn came 3% below ST, and incl Fx impact of -500 bps (we are unsure... More
KeyBanc on Baxter International (BAX), Believes Investors are 'Dissappointed' With Q2 2022 Earnings Report and Guidance Update
July 28, 2022 9:53 AM EDTKeyBanc analyst Matthew Mishan reiterated an Overweight rating and $87.00 price target on Baxter International (NYSE: BAX).
The analyst comments "We believe investors will view BAXs 2Q22 release and updated 2022 guidance as disappointing. 2Q revenue missed mostly on FX and weaker... More
